Market Spotlight: Polycystic Ovary Syndrome (PCOS)
|出版日期||內容資訊||英文 29 Pages
|熱門市場分析:多囊性卵巢症候群 (PCOS) Market Spotlight: Polycystic Ovary Syndrome (PCOS)|
|出版日期: 2019年11月29日||內容資訊: 英文 29 Pages||
本報告提供多囊性卵巢症候群 (PCOS)的治療藥市場相關分析，提供在疾病概要和患者數的轉變·預測，目前的主要的治療方法及臨床實驗·認證情形，PCOS治療藥市場趨勢預測 (今後10年份)，資本交易的動向，現在開發中臨床實驗的進展等調查。
This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2017, there were approximately 113.2 million (NIH criteria) to 188.7 million (Rotterdam criteria) prevalent cases of polycystic ovary syndrome (PCOS) in females aged 15-49 years worldwide, and expects that number to increase to between 119.5 million (NIH criteria) and 199.1 million (Rotterdam criteria) by
2026. The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor. These drugs are commonly administered via the oral or subcutaneous routes, with one product also being available in an intramuscular formulation.
Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, gonadotropinreleasing hormone receptor, and SGLT. These therapies are administered orally.
The overall likelihood of approval of a Phase I endocrine asset is 11.9%, and the average probability a drug advances from Phase III is 69.7%. Drugs, on average, take 9.3 years from Phase I to approval in the overall endocrine space.
There has been only one licensing agreement involving PCOS drugs during 2014-19. The deal was an exclusive licensing agreement signed in 2016 between Millendo and AstraZeneca for the worldwide development and commercialization rights to MLE4901. The deal value was not disclosed.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PCOS have been in the late phases of development, with approximately 79% of trials in Phase III-IV, and only 21% in Phase II.
The US has the highest number of PCOS clinical trials globally. Germany and the UK lead the major EU markets, while Indonesia and South Korea share the top spot in Asia.
Clinical trial activity in the PCOS space is dominated by completed trials. Merck KGaA has the highest number of completed clinical trials for PCOS, with five trials.
Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.
8 Clomiphene citrate
8 Antidiabetic agents
8 Aromatase inhibitors
9 Oral contraceptive pills
25 Sponsors by status
26 Sponsors by phase